The University of Manchester’s role in establishing nationally funded forefront services for neurofibromatoses

  • Evans, Dafydd (Participant)
  • Richard Ramsden (Participant)
  • Susan Huson (Participant)

Impact: Health impacts, Economic impacts, Societal impacts


Research conducted at the University of Manchester (UoM) has brought about significantly improved management of neurofibromatosis type 2 (NF2) and neurofibromatosis type 1 (NF1). The demonstration of a survival advantage in NF2 from specialist management centres by Evans and the pioneering work on brain stem/cochlear implants by Ramsden and team were deciding factors for the creation of nationally commissioned services for NF1 and NF2 in 2009 and 2010. All 850 patients with NF2 in England and ~800 complex NF1 patients are now managed through the national services. This specialist management of neurofibromatoses leads to improved life expectancy.
Impact date2009
Category of impactHealth impacts, Economic impacts, Societal impacts
Impact levelBenefit